GILD · 10-Q · 2026Q2 · Full report

Operating Expense Trends

GILEAD SCIENCES, INC. · 2026-08-06 · Importance 78 · Surprise 74 · No source text

Selling, general and administrative expense increased 41% to $1.9 billion in the second quarter of 2026 and 29% to $3.4 billion for the first six months. Selling and marketing expense rose primarily because of higher HIV promotional spending. General and administrative expense increased because of acquisition integration costs, including $332 million of acquisition-related stock-based compensation. Six-month general and administrative expense also included donations of equity securities to the Gilead Foundation.

Key facts

• Net loss for the three months ended June 30, 2026: $(10,496) million. source
• Net loss for the six months ended June 30, 2026: $(8,475) million. source
• Selling, general and administrative expenses for the six months ended June 30, 2026: $3,372 million. source
• General and administrative expenses included $332 million of stock-based compensation expenses related to the acquisitions of Arcellx, Ouro Medicines and Tubulis for the six months ended June 30, 2026. source
• Selling, general and administrative expenses for the three months ended June 30, 2026: $1,921 million. source
• Interest expense for the six months ended June 30, 2026: $487 million, a 5% decrease compared to the same period in 2025. source
• Selling and marketing expenses increased primarily due to higher HIV promotional expenses for the six months ended June 30, 2026. source
• Interest expense for the three months ended June 30, 2026: $247 million. source

Impact estimates